TScan Therapeutics, Inc. (NASDAQ:TCRX) Stock Holdings Lessened by Marathon Trading Investment Management LLC

Marathon Trading Investment Management LLC reduced its holdings in TScan Therapeutics, Inc. (NASDAQ:TCRX) by 73.3% during the second quarter, HoldingsChannel reports. The institutional investor owned 13,600 shares of the company’s stock after selling 37,400 shares during the period. Marathon Trading Investment Management LLC’s holdings in TScan Therapeutics were worth $80,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of TCRX. Pale Fire Capital SE lifted its position in TScan Therapeutics by 30.2% in the 4th quarter. Pale Fire Capital SE now owns 21,573 shares of the company’s stock valued at $126,000 after purchasing an additional 4,998 shares during the last quarter. Cannon Global Investment Management LLC bought a new stake in TScan Therapeutics in the 1st quarter valued at about $139,000. Tocqueville Asset Management L.P. bought a new stake in TScan Therapeutics in the 1st quarter valued at about $1,685,000. Vanguard Group Inc. lifted its position in TScan Therapeutics by 1.1% in the 1st quarter. Vanguard Group Inc. now owns 1,808,152 shares of the company’s stock valued at $14,357,000 after purchasing an additional 20,000 shares during the last quarter. Finally, Bank of New York Mellon Corp bought a new stake in TScan Therapeutics in the 2nd quarter valued at about $682,000. 82.83% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the stock. Wedbush reiterated an “outperform” rating and issued a $10.00 price objective on shares of TScan Therapeutics in a research report on Monday, August 12th. Needham & Company LLC reiterated a “buy” rating and issued a $11.00 price objective on shares of TScan Therapeutics in a research report on Monday, August 12th. Finally, HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of TScan Therapeutics in a research report on Tuesday, August 13th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $12.00.

TScan Therapeutics Stock Up 1.7 %

TScan Therapeutics stock opened at $5.54 on Thursday. The stock has a market cap of $293.45 million, a price-to-earnings ratio of -4.33 and a beta of 0.79. The company has a current ratio of 7.77, a quick ratio of 7.77 and a debt-to-equity ratio of 0.08. The company’s 50-day moving average price is $6.20 and its two-hundred day moving average price is $7.09. TScan Therapeutics, Inc. has a 52 week low of $2.43 and a 52 week high of $9.69.

TScan Therapeutics (NASDAQ:TCRX) last released its earnings results on Monday, August 12th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.02. The firm had revenue of $0.54 million for the quarter, compared to analysts’ expectations of $1.55 million. TScan Therapeutics had a negative net margin of 855.84% and a negative return on equity of 59.83%. On average, analysts expect that TScan Therapeutics, Inc. will post -1.36 EPS for the current fiscal year.

Insider Transactions at TScan Therapeutics

In other TScan Therapeutics news, Director Barbara Klencke acquired 5,000 shares of the stock in a transaction dated Monday, August 26th. The shares were bought at an average price of $5.53 per share, with a total value of $27,650.00. Following the purchase, the director now directly owns 40,000 shares of the company’s stock, valued at approximately $221,200. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, insider Zoran Zdraveski sold 164,686 shares of TScan Therapeutics stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $5.78, for a total value of $951,885.08. Following the transaction, the insider now owns 4,716 shares of the company’s stock, valued at approximately $27,258.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Barbara Klencke acquired 5,000 shares of the stock in a transaction dated Monday, August 26th. The stock was acquired at an average cost of $5.53 per share, for a total transaction of $27,650.00. Following the purchase, the director now directly owns 40,000 shares in the company, valued at $221,200. The disclosure for this purchase can be found here. Corporate insiders own 2.76% of the company’s stock.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.